Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUINOC: Fedovapagon for Nocturia in Men with BPH
NCT02637960Phase 3Completed
- Sponsor
- Vantia Therapeutics
- Start
- Mar 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fedovapagon in nocturia, sponsored by Vantia Therapeutics. Started Mar 2016; status: completed.
02
Drugs
fedovapagon
03
Conditions
nocturia
Beyond the preview
Go deeper on NCT02637960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637960.